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ABSTRACT
Cancer stem cells (CSC) may take advantage of the Warburg effect-induced 
siphoning of metabolic intermediates into de novo fatty acid biosynthesis to increase 
self-renewal growth. We examined the anti-CSC effects of the antifungal polyketide 
soraphen A, a specific inhibitor of the first committed step of lipid biosynthesis 
catalyzed by acetyl-CoA carboxylase (ACACA). The mammosphere formation capability 
of MCF-7 cells was reduced following treatment with soraphen A in a dose-dependent 
manner. MCF-7 cells engineered to overexpress the oncogene HER2 (MCF-7/HER2 
cells) were 5-fold more sensitive than MCF-7 parental cells to soraphen A-induced 
reductions in mammosphere-forming efficiency. Soraphen A treatment notably 
decreased aldehyde dehydrogenase (ALDH)-positive CSC-like cells and impeded 
the HER2’s ability to increase the ALDH+-stem cell population. The following results 
confirmed that soraphen A-induced suppression of CSC populations occurred through 
ACACA-driven lipogenesis: a.) exogenous supplementation with supraphysiological 
concentrations of oleic acid fully rescued mammosphere formation in the presence 
of soraphen A and b.) mammosphere cultures of MCF-7 cells with stably silenced 
expression of the cytosolic isoform ACACA1, which specifically participates in de novo 
lipogenesis, were mostly refractory to soraphen A treatment. Our findings reveal for 
the first time that ACACA may constitute a previously unrecognized target for novel 
anti-breast CSC therapies.
INTRODUCTION
Accumulating evidence indicates that the metabolic 
state of cancer stem cells (CSCs), a population of cancer 
cells capable of enhanced self-renewal, governs their 
tumor-initiating ability. Additionally, CSCs are resistant 
to conventional therapy and are significantly different 
from their differentiated cellular counterparts. Because 
metabolic reprogramming may control the ability of CSCs 
to avoid treatment and promote recurrence, successful 
metabolic therapy may eliminate these key drivers of 
tumor formation, progression, and recurrence [1-6]. 
Several attempts have been made to therapeutically 
modulate the metabolic state of cancer cells by treating 
with compounds that inhibit the most recognizable 
bioenergetic feature of tumor cells, i.e., aerobic glycolysis 
(the Warburg effect) [7-11]. However, efforts to inhibit 
glycolysis using the glucose analog 2-deoxyglucose (2-
DG), which accumulates in cells and inhibits glycolytic 
hexokinase (KH), or the small molecule dichloroacetate 
(DCA), which inhibits mitochondrial pyruvate 
dehydrogenase kinase (PDK) and forces pyruvate into 
the mitochondria to increase mitochondrial metabolism, 
remain unsatisfactory. In addition, these approaches 
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are not selective for either CSCs or more differentiated 
bulk tumor cells, and drugs that inhibit glycolysis do not 
necessarily result in increased mitochondrial metabolism 
and could result in the disruption of energy production 
and non-selective cell death. Thus, glycolysis inhibitors 
may be undesirably toxic to non-cancerous tissues that 
depend on glycolysis for energy production (i.e., skeletal 
muscle or brain tissues). CSCs are known to contain 
lower reactive oxygen species (ROS) levels than their 
cancerous epithelial-like progeny cells [12]. Therefore, 
one therapeutic alternative to consider is the re-activation 
of mitochondrial function and biogenesis, which in turn 
would impact the suppression of ROS-induced killing in 
CSCs, as opposed to acutely inducing energy starvation 
and cell death in all tissues utilizing glycolysis for energy 
production. In particular, the mitochondrial regulator 
metformin has been increasingly recognized as a strong 
therapeutic capable of targeting CSCs in pre-clinical 
models of human cancer [13-23]. 
Another possible treatment approach is related to 
the commonly observed upregulation of endogenous lipid 
biosynthetic pathways in cancer tissues. This so-called 
lipogenic phenotype fuels membrane biogenesis in rapidly 
proliferating cancer cells and renders cancer membrane 
lipids more saturated. The lipogenic phenotype also 
impacts fundamental cellular processes associated with 
cancer cell transformation, including signal transduction, 
gene expression, ciliogenesis, and response to therapy 
[24-30]. In the fatty acid synthesis pathway, acetyl-CoA is 
carboxylated to malonyl-CoA by acetyl-CoA carboxylase 
(ACACA). Both acetyl-CoA and malonyl-CoA are then 
used in a condensation reaction by the main lipogenic 
enzyme fatty acid synthase (FASN) to produce long-chain 
fatty acids. Of note, it is known that higher expression 
levels of lipogenic genes and proteins such as FASN are 
found in CSC subpopulations of breast cancer cell lines 
and that upregulation of de novo fatty acid biogenesis is 
a pre-requisite for the formation of pre-malignant lesions 
due to increased CSC survival [31-35]. Moreover, recent 
studies performed in induced pluripotent stem cells 
(iPSCs) have revealed that when activities of the ACACA 
and FASN lipogenic enzymes are inhibited, the efficiency 
of somatic reprogramming to stemness is decreased [30]. 
Coincidentally, ACACA and FASN are highly expressed 
in iPSCs. We recently hypothesized that the stemness 
features of cancer cells may take advantage of the 
Warburg effect-related ability of tricarboxylic acid (TCA) 
cycle intermediates to be siphoned into lipid biosynthesis 
metabolism for CSC self-renewal and survival. 
To test the hypothesis that the therapeutic targeting 
of endogenous lipogenesis may impact the CSC cellular 
state in heterogeneous breast cancer cell populations, we 
examined the polyketide soraphen A, which was chosen for 
these studies because its mechanism of ACACA inhibition 
is well defined [36-43]. Unlike RNA interference-based 
approaches [44], the rapidity of soraphen A-induced 
inhibition of lipid metabolism minimizes non-specific 
or adaptive changes caused by changes in cell fatty acid 
composition and cell growth. Our current results are the 
first to show that soraphen A treatment can inhibit the 
formation of mammospheres in a fatty acid-dependent 
manner, highlighting the potential value of ACACA as a 
novel metabolic target in breast CSC.
RESULTS
Soraphen A decreases mammosphere formation in 
MCF-7 breast cancer cells
 We first tested the ability of MCF-7 breast cancer 
cells to form tumor spheres when grown in suspension 
cultures in the presence of a range of concentrations 
of soraphen A (1, 5, 10, and 50 nmol/L). The MSFE 
was calculated as the number of sphere-like structures 
(diameter >50 µm) divided by the original number of cells 
seeded and expressed as the mean percentage (±SD). A 
subset (2.0 ± 0.01%) of untreated MCF-7 breast cancer 
cells formed bona fide mammospheres upon initial plating, 
and this result confirms previous reports that MCF-7 
cell cultures intrinsically contain a SC-like population. 
Interestingly, the spheroid formation capability of MCF-
7 cells was significantly reduced following treatment 
with increasing concentrations of soraphen A in a dose-
dependent manner (50% reduction at 15 nmol/L soraphen 
A; Fig. 1, left and middle panels). Although the ability of 
some CSC-like cellular states to survive and proliferate as 
floating spherical colonies under anchorage-independent 
conditions at low frequencies (1-3%) is commonly 
regarded as an in vitro surrogate of the self-renewal 
and tumor-initiating capacity exclusively possessed by 
CSCs, it should be acknowledged that mammosphere 
formation assays can also be viewed as bona fide assays 
for evaluating the number of anoikis-resistant cells within 
heterogenous cancer populations. To unambiguously 
validate the anti-CSC effects of soraphen A, anoikis was 
induced by plating MCF-7 cells into culture dishes that 
had been coated with poly-2-hydroxyethyl methacrylate 
(Poly-HEME) in the absence or presence of soraphen A 
(50 nmol/L; 48 h) prior to replating a viable fraction of 
the suspended samples in serum- and soraphen A-free 
mammosphere medium. Remarkably, soraphen A-treated 
anoikis cultures reduced by 50% their mammosphere-
formation efficiency after removal of the drug (Fig. 1, right 
panel). Importantly, the soraphen A-induced reduction 
in mammosphere formation was not due to non-specific 
toxicity, as MTT-based experiments in monolayer cultures 
of MCF-7 cells showed that cell viability remained as 
high as 90% in the presence of identical nanomolar 
concentrations of soraphen A (Fig. 1, middle panels). 
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Soraphen A eliminates the HER2-enhanced 
formation of mammospheres
We next examined whether treatment with soraphen 
A was sufficient to prevent the well-recognized ability of 
the oncogene HER2 to expand the breast CSC population. 
MCF-7 cells engineered to overexpress HER2 (MCF-
7/HER2) exhibited a significantly increased ability to 
form mammospheres (3.8 ± 0.1%) compared to parental 
MCF-7 cells. However, this enhanced spheroid formation 
capability of MCF-7/HER2 cells was drastically reduced 
following treatment with soraphen A, which decreased 
the MSFE by 50% at ∼3 nmol/L (i.e., a Soraphen A 
concentration 5 times lower than that needed to decrease 
MSFE by 50% in MCF-7 parental cells). The highest 
dose of the soraphen A (50 nmol/L) elicited inhibitory 
effects of ∼80% compared to the basal MSFE found in 
untreated MCF-7/HER2 tumor sphere cultures (Fig. 2). 
Mammosphere formation was also drastically decreased 
by soraphen A treatment in SKBR3 cells, which are 
a natural model of HER2 overexpression and HER2 
dependency for cell proliferation and survival (data not 
shown). 
Similar to the results obtained with MCF-7 cells, 
the reductions in mammosphere formation were not 
due to non-specific soraphen A toxicity, as identical 
concentrations of the drug had no drastic impact on MCF-
7/HER2 cell viability under adherent culture conditions. 
These findings strongly suggest that the mechanism of 
action targeted by nanomolar concentrations of soraphen A 
is not essential for the bulk breast cancer cell population. 
Soraphen A decreases the percentage of breast 
cancer cells expressing the CSC marker 
ALDEFLUOR.
 The drastic decrease in mammosphere formation 
rates observed following treatment of MCF-7 and MCF-
7/HER2 cancer cell populations with Soraphen A certainly 
Figure 1: Pharmacological blockade of ACACA activity inhibits mammosphere formation in MCF-7 cells. Left. Figure 
shows representative light microscope representations of mammospheres formed by MCF-7 cells growing in sphere medium for 7 days 
in the absence or presence of graded concentrations of Soraphen A, as specified (20X magnifications). Middle. MSFE of MCF-7 cells 
was calculated as the number of mammospheres (diameter >50 µm) formed in 7 days divided by the original number of cells seeded and 
expressed as percentage means (columns) ± SD (bars). Re-feeding of mammospheres cultures with Soraphen A and/or sphere medium 
was performed on days 3 and 5. The metabolic status of monolayer cultures of MCF-7 cells treated with increasing concentrations of 
Soraphen A was measured using MTT uptake assays, and cell viability is expressed as % uptake relative to untreated control cells (= 100% 
cell viability). Right. MCF-7 cells were trypsinized into a single cell suspension, and 2 mL was cultured on poly-HEME-coated plates at 
a density of ∼105 cells/mL (total of 2 x 105 cells/well) in the absence or presence of 50 nmol/L soraphen A and then incubated at 37 oC 
for an additional 48 h. Cells that were visibly anoikis-resistant with intact plasma membranes, i.e., excluding trypan blue stain, were then 
cultured in soraphen A-free mammosphere medium for 7 days following the same procedure as described above. The results are presented 
as the mean (columns) ± SD (bars) of 2 independent experiments performed in triplicate. *P < 0.01 and **P < 0.001, statistically significant 
differences from the control group. n. s. not statistically significant.
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provided preliminary insight as to the Soraphen A’s 
mechanism of action, in particular to its putative ability to 
specifically remove CSCs from the bulk population. We 
therefore envisioned that Soraphen A might specifically 
suppress aldehyde dehydrogenase (ALDH)-positive CSC-
like cells. Using flow cytometry and the ALDEFLUOR® 
reagent, we first confirmed the presence of an enhanced 
aldefluor-positive sub-population in MCF-7 and MCF-7/
HER2 cells. In Soraphen A-naïve MCF-7 cell populations, 
approximately 2.4% of the cells expressed high ALDH 
activity (Fig. 3A). Interestingly, in Soraphen A-treated 
MCF-7 cell populations, solely 1.5% of the cells remained 
ALDH-positive. We confirmed that overexpression of 
HER2 increased the aldefluor-positive population almost 
twofold compared to MCF-7 parental cells; remarkably, 
the aldefluor-positive cell content drastically decreased 
from 4% in Soraphen A-naïve MCF-7/HER2 cell 
populations to 1.8% in Soraphen A-treated MCF-7/HER2 
cells (Fig. 3B). 
Soraphen A suppresses HER2-enhanced 
mammosphere formation by blocking endogenous 
lipogenesis
 We next sought to unambiguously establish that 
soraphen A suppresses mammosphere formation by 
inhibiting de novo fatty acid biogenesis (Fig. 4A, left 
panel). Therefore, we determined the rescue potential of 
oleic acid when the lipogenic pathway was specifically 
blocked through treatment with soraphen A. The strong 
inhibitory effects of soraphen A on the mammosphere 
formation capability of MCF-7/HER2 cells were fully 
counteracted by supplementation of the mammosphere 
medium with micromolar concentrations of oleic acid (100 
µmol/L; Fig. 4A, middle panel). 
Notably, in the presence of a gradient of non-
cytotoxic micromolar concentrations of the FASN 
inhibitor C75, MCF-7 cells lost their ability to develop 
mammospheres in a dose-dependent manner with the 
highest dose of C75 (10 µmol/L) eliciting consistently 
greater inhibitory effects than the lowest dose (0.1 
µmol/L). Indeed, 10 µmol/L C75 dramatically suppressed 
Figure 2: Pharmacological blockade of ACACA 
activity inhibits mammosphere formation in MCF-7/
HER2 cells. Left. Figure shows representative light microscope 
representations of mammospheres formed by MCF-7/HER2 
cells growing in sphere medium for 7 days in the absence or 
presence of graded concentrations of Soraphen A, as specified 
(20X magnifications). Right. MSFE of MCF-7/HER2 cells was 
calculated as the number of mammospheres (diameter >50 µm) 
formed in 7 days divided by the original number of cells seeded 
and expressed as percentage means (columns) ± SD (bars). Re-
feeding of mammospheres cultures with Soraphen A and/or 
sphere medium was performed on days 3 and 5. The metabolic 
status of monolayer cultures of MCF-/HER2 cells treated with 
increasing concentrations of Soraphen A was measured using 
MTT uptake assays, and cell viability is expressed as % uptake 
relative to untreated control cells (= 100% cell viability). The 
results are presented as the mean (columns) ± SD (bars) of 2 
independent experiments performed in triplicate. *P < 0.01 and 
**P < 0.001, statistically significant differences from the control 
group. n. s. not statistically significant.
Figure 3: Pharmacological blockade of ACACA 
activity impedes HER2-induced expansion of stem 
cell population. MCF-7 cells (A) and HER2-overexpressing 
MCF-7/HER2 cells (B) were subjected to the ALDEFLUOR® 
assay to identify cells with high ALDH activity in the absence 
or presence or Soraphen A (10 nmol/L, 3 days with daily re-
feeding). The ALDH inhibitor DEAB was used as a negative 
control. The cells without inhibitor shifted to the right and were 
considered ALDH-positive cells. 
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the MSFE by > 90% (Fig. 4A, right panel).
Soraphen A suppresses mammosphere formation 
via ACACA
 We next evaluated whether soraphen A-induced 
inhibition of mammosphere formation occurred through 
the specific targeting of ACACA. To do so, we reevaluated 
the effects of soraphen A on the mammosphere capability 
of MCF-7 cells in which the ACACA gene was stably 
silenced via lentiviral-delivered small hairpin RNA 
(MCF-7shACACA1). First, we confirmed differences in 
mammosphere formation between conditions of ACACA 
chemical inhibition versus ACACA gene silencing. A 
previous study reported that knockdown of ACACA 
recapitulated AMPK activation and facilitated anchorage-
independent growth [45]. Our data indicated that ACACA 
silencing elicited stronger mammosphere formation in 
MCF-7shACACA1 cells (Fig. 4B). In addition, we observed 
that the enhanced mammosphere formation ability of 
MCF-7shACACA1 cell was mostly refractory to soraphen A 
treatment even at concentrations of 100 nmol/L, which 
were able to fully suppress the mammosphere formation 
capability of MCF-7 parental cells. 
Figure 4: Soraphen A suppresses self-renewal growth of CSC-like cells by blocking ACACA-catalyzed endogenous 
lipogenesis. A. Right. MSFE of MCF-7/HER2 cells was calculated as the number of mammospheres (diameter >50 µm) formed in 7 
days in the absence or presence of graded concentrations of Soraphen A and co-exposed to 100 µmol/L oleic acid, as specified, divided 
by the original number of cells seeded and expressed as percentage means (columns) ± SD (bars). Re-feeding of mammospheres cultures 
with sphere medium, Soraphen A, and/or oleic acid was performed on days 3 and 5. Left. MSFE of MCF-7 cells was calculated as the 
number B. MSFE of MCF-7 and MCF-7shACACA1 cells was calculated as the number of mammospheres (diameter >50 µm) formed in 7 days 
in the absence or presence of 100 nmol/L Soraphen A divided by the original number of cells seeded and expressed as percentage means 
(columns) ± SD (bars). Re-feeding of mammospheres cultures with Soraphen A and/or sphere medium was performed on days 3 and 5. 
The results in A and B are presented as the mean (columns) ± SD (bars) of 2 independent experiments performed in triplicate. *P < 0.01 
and **P < 0.001, statistically significant differences from the control group. n. s. not statistically significant. C. MCF-7 and MCF-7/HER2 
cells, untreated or treated for 3 days with 50 nmol/L soraphen A, were exposed for 60 min to H2DCF-DA and their fluorescence intensity 
was measured by flow cytometry. Figure shows representative scatter plot histograms of DCF fluorescence. The columns at the interior 
the histograms show relative measurements of ROS levels in soraphen A-treated MCF-7 and MCF-7/HER2 cells compared to untreated 
controls (=100%). *P < 0.01 and **P < 0.001, statistically significant differences from the control group.
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DISCUSSION
Frustrated by the gene-centric limitations of 
conventional approaches used to identify molecular 
markers associated with rare tissue-specific sub-
populations of CSCs, we recently postulated that CSCs 
may display unique metabolic features that distinguish 
them from the bulk of tumor cells. We hypothesized that 
these metabolic properties may constitute a basis for 
developing new therapeutic strategies to eliminate CSCs 
[1]. One of the properties of stem/progenitor cells is their 
ability to survive under anchorage-independent conditions 
and generate mammospheres. Our current data are the first 
to show a highly significant decrease in mammosphere 
formation in the presence of the polyketide fungicide 
soraphen A. These results confirm that the lipogenic 
enzyme ACACA might represent a novel target for anti-
breast CSC therapies. These findings, together with the 
ability of chemical inhibitors of FASN activity such as 
C75 to recapitulate the anti-mammosphere activity of 
the ACACA inhibitor soraphen A, also confirm that de 
novo fatty acid biogenesis, a pathway that is frequently 
deregulated during breast carcinogenesis, plays a 
functional role in CSC self-renewal and survival. 
Therapeutic exploitation of the lipogenic pathway 
in cancer should consider the effects of blocking one 
metabolic enzyme on the expression and activity of other 
metabolic genes. In particular, it is essential to consider 
that alternate mechanisms/pathways might compensate 
for the inhibition of any enzyme in the lipogenic 
pathway. For example, silencing of ATP citrate lyase 
(ACLY), a cytosolic enzyme that converts citrate into a 
shared precursor for fatty acid and mevalonate synthesis 
such as acetyl-CoA, is sufficient to counteract stem cell 
characteristics induced in diverse cancer cell systems. 
Moreover, the expression of FASN, which catalyzes 
the rate-limiting reaction for fatty acid synthesis, and 
HMGCR, which is the rate-limiting enzyme in the 
mevalonate pathway, were both shown to be significantly 
enhanced after ACLY knockdown. These results suggest 
that ACLY deficiency forces cancer cells to upregulate 
the expression of downstream genes in fatty acid and 
cholesterol synthesis pathways to compensate for the loss 
of ACLY. Of note, this type of compensation that occurs 
during the therapeutic targeting of lipogenesis-related 
enzymes such as ACLY might be unacceptable for cancer 
treatment [43, 46]. We acknowledge that our study failed 
to evaluate whether the chemical perturbation of ACACA 
promoted major changes in the expression profile of 
other metabolic genes. However, the rapidity of soraphen 
A-induced inhibition of de novo fatty acid biogenesis 
appeared to minimize the occurrence of non-specific or 
adaptive changes that could be switched on in response 
to changes in cell fatty acid composition and cell growth. 
In fact, the chemical inhibition of ACACA mediated by 
soraphen A promoted the opposite effect on mammosphere 
formation as stable genetic silencing of the cytosolic 
isoform ACACA1, which specifically participates in de 
novo lipogenesis. As reported in the study by Jeon et al. 
[45], knockdown of ACACA was found to recapitulate 
AMPK activation and facilitate anchorage-independent 
growth. Thus, MCF-7 cells with stably silenced expression 
of the cytosolic isoform ACACA1 demonstrate enhanced 
mammosphere formation capacity. Interestingly, MCF-
7shACACA1 cells were largely refractory to concentrations 
of soraphen A that completely suppressed mammosphere 
formation in MCF-7 parental cells. This finding, as well 
as the data showing that exogenous supplementation with 
supraphysiological concentrations of the monounsaturated 
fatty acid oleic acid fully rescued the ability of MCF-7/
HER2 cells to form mammospheres in the presence 
of soraphen A, mechanistically confirm that soraphen 
A-induced suppression of breast CSC populations 
specifically occurs via blockade of ACACA1-driven 
lipogenesis. 
Soraphen A-induced inhibition of ACACA has been 
shown to augment the accumulation of unsaturated fatty 
acids derived from saturated and polyunsaturated fatty 
acid precursors by impacting both fatty acid elongation 
and by disrupting pathways where both elongases and 
desaturases are utilized. The inhibition of ACACA 
leads to a significant shift in fatty acid metabolism, 
whereby saturated fatty acids and essential fatty acids are 
desaturated but not elongated [42]. Thus, it is tempting to 
speculate that unlike RNA interference-based approaches 
[45], the rapid ability of soraphen A to acutely disrupt 
a strong functional link between ACACA activity and 
the synthesis of saturated-, monounsaturated-, and 
polyunsaturated fatty acids through the control of fatty 
acid elongase activity might underlie soraphen A-mediated 
elimination of breast CSCs. Other studies have found 
that reversing the lipogenic switch in cancer cells with 
soraphen A treatment leads to a marked decrease in 
saturated and mono-unsaturated phospholipid species 
and an increase in the relative degree of polyunsaturation. 
Because polyunsaturated acyl chains are more susceptible 
to peroxidation, soraphen A-induced acute inhibition of 
lipogenesis may increase the levels of peroxidation end 
products and render cells more susceptible to oxidative 
stress-induced cell death. One of the properties of 
anoikis-resistant stem/progenitor cells is their ability 
to survive in anchorage-independent conditions and 
generate mammospheres. Thus, the soraphen A-induced 
acute blockade of endogenous lipogenesis may impair 
the intrinsic ability of CSCs to escape anoikis due to 
increased oxidative damage and starvation and cell death 
in detached microenvironmental conditions. In this regard, 
exposure of breast cancer cells to soraphen A led to a 
marked augmentation of cells ability to oxidize H2DCF-
DA (Fig. 4C); because H2DCF oxidation by ROS results in 
formation of strongly fluorescent DCF which is considered 
to be a marker of ROS abundance and low levels of ROS 
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maintain characteristics of ROS, it might be tempting 
to suggest that increasing ROS might be part of the 
pharmacological mechanism through which soraphen A 
promotes the loss of breast CSCs. Additionally, soraphen 
A may alter the formation and functioning of membrane 
microdomains such as lipid rafts, a recently recognized 
mechanism involved in the escape from anoikis-induced 
cell death [47-52]. 
Chemoresistant cell subpopulations from breast cell 
lines have been shown to possess high levels of ALDH 
activity. By virtue of those high levels of ALDH activity, 
FACS can track chemoresistant CSC-like subpopulations 
as ALDH-positive cells. Indeed, in several types of tumors 
including breast cancer, cancer cell subpopulations that 
are enriched for cancer-initiating activity have been 
readily identified by flow cytometry analysis using the 
ALDEFLUOR® reagent to identify cells with high levels 
of ALDH activity [53-56]. We confirmed earlier studies 
showing that HER2-overexpressing breast cancer cells 
contain readily detectable higher amounts of ALDH-
positive cells [57]. What we believe is remarkable here 
is that treatment with no cytotoxic concentrations of 
Soraphen A notably reduced the number of ALDH-positive 
cells to those levels commonly found in breast cancer 
cell lines expressing the lowest level of ALDH activity. 
Moreover, Soraphen A treatment was sufficient to impede 
the HER2’s ability to increase the stem cell population. 
Therefore, in the presence of Soraphen, the decrease in 
ALDH activity may account, at least in part, for the loss of 
stemness of breast CSCs. This is very interesting since the 
ALDH-positive cells represent the chemosensitive fraction 
of biologically aggressive breast tumors and it indicates 
the potential of Soraphen A-like molecules for eliminating 
ALDH-positive chemoresistant cell subpopulations. 
In summary, our findings confirm the importance 
of de novo fatty acid biogenesis in CSC self-renewal and 
survival and reveal for the first time that ACACA might 
constitute a previously unrecognized target for novel anti-
breast CSC therapies. A large number of nanomolar small-
molecule ACACA inhibitors have been developed, and 
several have been evaluated in clinical trials for metabolic 
diseases such as obesity and metabolic syndrome [58-60]. 
The potency and mechanism of ACACA inhibition by 
soraphen A strongly suggest that pharmacological targeting 
of the soraphen A binding subunit dimerization site (i.e., 
the biotin carboxylase (BC) domain of the enzyme) may 
be useful to identify potent, efficacious ACACA inhibitors 
for cancer intervention. Using state-of-the art structure-
based drug design and crystal structures of human ACACA 
BC domain, Nimbus Discovery (Cambridge, MA) recently 
identified a unique series of allosteric inhibitors with 
low nanomolar potency (ND654, ND646) that bind to 
the soraphen A binding site. These inhibitors show anti-
neoplastic properties against human non-small cell lung 
cancer (NSCLC) and hepatocarcinoma cells in vitro and 
in vivo [61, 62]. If further studies support the anti-CSC 
activity of these drug-like allosteric inhibitors to bind the 
BC domain of ACACA with high potency and selectivity, 
our current findings may open new avenues for exploring 
potential anti-lipogenesis treatments to successfully target 
breast CSCs. 
MATERIALS AND METHODS
Drugs and reagents
 Soraphen A purified from the myxobacterium 
Sorangium cellulosum was kindly provided by Drs. 
Klaus Gerth and Rolf Jansen (Hemholtz Zentrum für 
Infektionsforschung GmbH, Braunschweig, Germany). 
Oleic acid was purchased from Sigma. C75 was purchased 
from Alexis Biochemicals (San Diego, CA). Soraphen A 
and C75 were dissolved in DMSO, and stored in the dark 
as stock solutions at -20 oC until utilization. 
Culture conditions
 MCF-7 human breast cancer cells were obtained 
from the American Type Culture Collection (ATCC). 
The cells were routinely grown in improved MEM 
(IMEM;BioSource International; Invitrogen S.A., 
Barcelona, Spain) supplemented with 5% fetal bovine 
serum (FBS) and 2 mmol/L L-Glutamine. The cells were 
maintained at 37°C in a humidified atmosphere of 95% 
air and 5% CO2. The construction of pBABE/HER2 
retroviruses and retroviral infection of MCF-7 cells to 
generate MCF-7/pBABE and MCF-7/HER2 cells have 
been described elsewhere [44]. The cells were screened 
periodically for Mycoplasma contamination.
Mammosphere culture.
Mammospheres were generated from single cells of 
the MCF-7, MCF-7/HER2, and MCF-7shACACA1 cell lines 
seeded at 103 cells/cm2 in six-well ultralow attachment 
plates (Corning Inc.). The sphere medium consisted of 
F-12/DMEM containing 5 mg/mL insulin, 0.5 mg/mL 
hydrocortisone, 2% B27 (Invitrogen Ltd.), and 20 ng/mL 
epidermal growth factor. The medium was made semi-
solid by the addition of 0.5% methylcellulose (R&D 
Systems, Minneapolis, MN) to prevent cell aggregation.
Mammosphere-forming efficiency.
The mammosphere-forming efficiency (MSFE) was 
calculated as the number of sphere-like structures (large 
diameter >50 µm) formed in 7 days divided by the original 
number of cells seeded and expressed as a percentage 
(mean ± SD).
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Anoikis Assay
 6-well tissue plates were coated with 200 µl (12 mg/
mL in 95% ethanol) of poly-(2-hydroxyethyl methacrylate) 
(poly-HEME; Sigma) by incubation overnight at 40 oC. To 
perform the anoikis assay, MCF-7 cells were trypsinized 
into a single cell suspension, and 2 mL was cultured in 
poly-HEME-coated plates at a density of ∼105 cells/mL 
(total of 2 x 105 cells/well) in the absence or presence of 
50 nmol/L soraphen A in Dulbecco’s Modified Eagle’s 
medium with 10% fetal bovine serum. 
Metabolic status assessment (MTT-based cell 
viability assays)
Cell viability was determined using a standard 
colorimetric MTT (3-4,5-dimethylthiazol-2-yl-2, 
5-diphenyl-tetrazolium bromide) reduction assay. 
Exponentially growing cells were harvested by 
trypsinization, seeded at a concentration of ~2.5 x 103 
cells/200 μL/well in 96-well plates, and allowed to attach 
overnight. The medium was then removed, and fresh 
medium containing various concentrations of soraphen 
A was added to the cultures as specified. Control cells 
without soraphen A were cultured in parallel using 
the same conditions with comparable media changes. 
Following treatment (5 days), the medium was removed 
and replaced with fresh drug-free medium (100 μL/well), 
and MTT (5 mg/mL in PBS) was added to each well at 
a 1/10 volume. After incubation for 2–3 h at 37°C, the 
supernatants were carefully aspirated, and 100 μL of 
DMSO was added to each well. The plates were agitated 
to dissolve the crystal product. The optical density (OD) 
was measured at 570 nm in a multi-well plate reader. 
The cell viability effects resulting from exposure to 
soraphen A were analyzed as percentages of the control 
cell absorbances, which were obtained from control wells 
treated with appropriate concentrations of the soraphen A 
vehicle and processed simultaneously. For each treatment, 
cell viability was evaluated as a percentage using the 
following equation: (OD570 of treated sample/OD570 of 
untreated sample) x 100. 
ALDEFLUOR® activity assay 
The ALDEFLUOR® assay (Stem Cell Technologies) 
quantifies ALDH activity by measuring the conversion 
of the ALDH substrate BODIPY aminoacetaldehyde 
to the fluorescent product BODIPY aminoacetate. 
Briefly, cells were suspended in ALDEFLUOR assay 
buffer containing the fluorescent ALDH substrate 
BODIPY-aminoacetaldehyde (BAAA) and incubated 
for 45 min at 37 oC. The assay buffer also contained a 
transport inhibitor to prevent efflux of BAAA from the 
cells. BAAA passively diffuses into live cells and is 
then converted by intracellular ALDH into a negatively 
charged product (BODIPY-aminoacetate) that is retained 
inside cells, labeling the cells with a bright fluorescent 
signal. After a washing step, the brightly fluorescent 
ALDH-expressing cells (ALDHbright) were detected in 
the green fluorescence channel (FL1; 520–540 nm) on a 
FACSCalibur instrument (BD Biosciences). A sample of 
cells was further stained with a specific ALDH inhibitor, 
diethylaminobenzaldehyde (DEAB) (Sigma), to serve 
as a negative control for each experiment. Because only 
cells with an intact cellular membrane can retain the 
ALDH1 reaction product, only viable ALDHbright cells 
were identified. Cells incubated with BAAA and DEAB 
were used to establish the background signal and define 
the ALDHbright region. Incubation of cells with the substrate 
in the absence of DEAB induced a shift in the BAAA 
fluorescence and defined the ALDHbright population.
Lentiviral transduction
Pre-packaged lentiviral particles that either 
encoded a non-targeting shRNA (negative shRNA, sc-
108080) or sequences specifically targeting the human 
ACCα(ACACA1) gene (sc-40312-V) were purchased 
from a commercial provider (Santa Cruz Biotechnology, 
Inc.). To infect MCF-7 cells with virus, the regular 
medium was replaced with culture medium containing 
5 µg/mL polybrene (Santa Cruz Biotechnology, sc-
124220). MCF-7 cells were then exposed to lentiviruses 
for 48 h. The lentiviral shRNA particles also encode a 
puromycin resistance gene for transduction selection. 
After infection, the cells were washed and grown 
in culture medium containing 10 μg/mL puromycin 
dihydrochloride (Sigma, P9620) for an additional 72 h. 
The MCF-7 cells were allowed to proliferate for at least 1 
week before any experimental procedures. To monitor the 
lentiviral transduction efficiency and transgene expression 
during the experiment we incubated additional subsets of 
MCF-7 cells with lentiviral particles encoding a green 
fluorescence protein (GFP) reporter (sc-108084). The 
transduction efficiency (>90%) was calculated as the ratio 
of the number of GFP-positive cells to the total number of 
cells from five random visual fields in three independent 
culture experiments.
Reactive Oxygen Species (ROS) Detection.
Untreated cells as well as cells treated with soraphen 
A were incubated 60 min with 10 μmol/L 2’,7’-dihydro-
dichlorofluorescein-diacetate (H2DCF-DA) (Invitrogen/ 
Molecular Probes) at 37˚C. Cellular green fluorescence 
was then measured by flow cytometry. Following 
oxidation by ROS and peroxides within cells the non-
fluorescent substrate H2DCF-DA is converted to the highly 
Oncotarget8314www.impactjournals.com/oncotarget
fluorescent derivative DCF [63-65]. The cell-permeant 
non-fluorescent H2DCF-DA upon cleavage of the acetate 
moiety by intercellular esterases and oxidation by ROS is 
converted to strongly fluorescent DCF and thus reports the 
ROS abundance.
Immunoblotting 
Testing for the total expression level of ACACA1 
was performed by immunoblotting procedures using the 
ACCα (H-76) sc-30212 rabbit polyclonal antibody (Santa 
Cruz Biotechnology, Inc.) according to the manufacturer’s 
instructions.
Statistical analysis
The results are presented as the mean ± SD for 
at least three repeated individual experiments for each 
group. The analyses were performed using XLSTAT 
2010 (AddinsoftTM). A P-value ≤ 0.01 was considered 
statistically significant.
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